Operator instructions] The conference is being recorded. [Operator instructions] A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends.

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer multiple sclerosis drug Kesimpta exceeded forecasts.

NVS' fourth-quarter earnings and sales beat estimates. Based on the strong momentum of the company???s key drugs, it provides an encouraging outlook for 2025.